PartnershipJun 3, 2026, 08:31 AM
Alpha Tau, Tolmar Partner for Alpha DaRT Prostate Cancer US Commercialization
AI Summary
Alpha Tau Medical and Tolmar International announced a strategic collaboration to develop and commercialize Alpha DaRT for prostate cancer in the U.S. Tolmar will make an initial $20 million equity investment in Alpha Tau at a 25% premium and contribute $15 million towards a new U.S. manufacturing facility. The agreement includes up to $161.5 million in clinical, regulatory, and commercial milestones for the initial indication, with an option to expand into bladder cancer. Tolmar gains exclusive U.S. commercialization rights for prostate cancer, while Alpha Tau will manufacture the product and lead clinical development.
Key Highlights
- Tolmar to invest $20M in Alpha Tau equity at $11.99/share, a 25% premium to VWAP.
- Tolmar will pay $15M towards a new Alpha DaRT production facility in the U.S.
- Alpha Tau is eligible for up to $96.5M in development and regulatory milestones.
- Alpha Tau is eligible for up to $65M in commercial milestone payments.
- Tolmar gains exclusive U.S. commercialization rights for prostate cancer for 20 years.
- Tolmar has an option to expand into U.S. bladder cancer with additional payments.
- Alpha Tau will manufacture Alpha DaRT, selling to Tolmar at 60% of net sales.
Price Impact
More from DRTS